EpiSante Biomedical | DNA methylation analysis | cancer management

About Us

Brief IntroductionEpiSante Biomedical - Brief Introduction | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
Core TechnologyEpiSante Biomedical - Core Technology | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy

Core Technology

Whole Genome Methylation Analysis Platform Technology

Conducting DNA methylation analysis on the whole genome to obtain a comprehensive and accurate methylation profile, and screening out methylation markers related to diseases.

Qualitative and Quantitative Methylation Analysis

Using bisulfite conversion technology for qualitative and quantitative analysis of methylated genes, such as: COBRA, qMSP, Pyrosequencing, Bisulfite Sequencing, Methylation NGS, etc.

Liquid Biopsy Handling

A small amount of cell-free DNA (cfDNA) is extracted from the blood for methylation analysis. This is a non-invasive test, reducing the discomfort and risk to patients, and is more suitable for continuous monitoring. It is a mainstream testing method in precision medicine.

Kit Development

Developing a series of methylation-related kits, including cfDNA extraction, bisulfite conversion, qMSP reagents, etc., characterized by easy operation, high efficiency, and good reproducibility.

Multi-center Clinical Trial

In collaboration with several teaching hospitals, a multi-center clinical trial is conducted to accumulate rich clinical trial experience.

Clinical Data Analysis

Possessing strong clinical data analysis capabilities, utilizing biostatistics, big data analysis, biological pathway analysis, molecular interaction analysis, etc., to identify methylation markers related to diseases.

We have established a whole-genome methylation analysis platform technology, which uses CpG microarray or methylation next-generation sequencing (NGS), and after big data analysis, it can screen out novel DNA methylation markers. This platform technology can be applied to many fields of research, such as: cancer, neuroscience, environmental toxins, stem cell research, aging, metabolic diseases, immune diseases, cell therapy, etc. We have used this platform technology to successfully develop liver cancer early screening, surgery prognosis, ablation monitoring, and companion diagnostics of immunotherapy.